Clinical Trials

Syntara are global leaders in amine oxidase chemistry and biology with more than a decade of experience in this field. This has resulted in extensive collaborations with scientific and clinical thought leaders worldwide and multiple publications in high impact scientific journals.

Syntara’s drug pipeline includes drugs at discovery, pre clinical, clinical phase 1 and phase 2 stage. Syntara has active clinical programs in three therapeutic areas:

null

Cancer

null

Skin scarring

null

Neurodegenerative disease

Potential to deliver near term value

Pipeline creates multiple opportunities in high value markets

 

Drug Candidate Indication Phase Anticipated Upcoming Milestones Addressable Market (US$)
SNT-5505 Myelofibrosis Phase 2 Interim 12 month data Q2 2025 ~$1 billion1
Myelodysplastic Syndrome
Low & intermediate Risk + High risk trials		 Phase 1c/2 Low/Int Risk Data H2 25
High Risk – Grant Pending		 ~$3.2 billion2
Oral and Topical
Pan-LOX inhibitors		 Scar prevention Phase 2 Data H2 2025 ~$3.5 billion3
Modification of scarring process Phase 1c Pilot study in keloid scars planned ~$3.5 billion4
SNT-4728 IRBD and Parkinson’s Disease Phase 2 Data H2 2025 ~$3.5 billion5

 

1) MF: Addressable market, The Myelofibrosis market size across the 8MM was valued at $2.39 billion in 2021 : https://www.globaldata.com/store/report/myelofibrosis-market-analysis/

2) MDS: Addressable market, MYELODYSPLASTIC SYNDROME TREATMENT MARKET ANALYSIS, https://www.coherentmarketinsights.com/market-insight/myelodysplastic-syndrome-treatment-market-775

3) Scar Prevention: Global Scar Market 2020 page 40 and 71; Total scar treatment market  in 2019 exceeded US$19b. Keloid and hypertrophic scar segment ~US$3.5b

4) Scar modification: Addressable market, Global Scar Market 2020 page 40 and 71. Total scar treatment market in 2019 exceeded US$19b. Keloid and hypertrophic scar segment ~US$3.5b

5) IRBD / Parkinson’s Addressable market, Parkinson’s Disease market size across the 7MM was valued at $3.4 billion in 2019 and is expected to achieve a CAGR of more than 6% during 2019-2029. https://www.globaldata.com/store/report/parkinsons-disease-major-market-analysis

 

 

Syntara

Collaborating with scientific and clinical thought leaders worldwide and multiple publications in high-impact scientific journals.